PHA Europe and Cambridge-based electronRx have partnered to improve the quality of life for pulmonary hypertension sufferers.
PHA Europe includes 37 members from 32 countries who share the goal of finding a cure for pulmonary hypertension and enhancing the quality of life for those who suffer from the condition.
The partnership expands on electronRx’s objective to improve the quality of life and empower individuals with respiratory disorders including pulmonary hypertension (PH) to make wise decisions.
The funds earned by electronRx will benefit PHA Europe’s five primary areas of focus—improving patient groups’ access to quality care, raising awareness and screening, promoting clinical research and innovation, and guaranteeing the provision of psychosocial support.
Read Also: Combined chemotherapy and immunotherapy improves outcomes in PAH
Dr. Bipin Patel, CEO of electronRx, said: “We are honored to partner with PHA Europe and help improve the quality of life of patients living with PH. At electronRx, we are committed to assisting people to breathe with our simple innovative technology.
“Supporting those affected by breathing conditions such as PH is critical to us, our focus is on the people we’re helping. Behind every line of code and every task is a person who deserves better health and a better quality of life. Supporting associations like PHA Europe reflects our values and dedication at electronRx, enabling us to make a real difference in millions of people’s lives.”
Gerald Fischer, CEO of PHA Europe, added: “The generous support from electronRx enhances our mission. Together, we can provide a better quality of life and find a cure for PH. We are grateful for their commitment and look forward to a fruitful partnership.”
